- Home
- CLNN vs ALLK Comparison
CLNN vs ALLK Comparison
Compare CLNN & ALLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLNN
- ALLK
- Stock Information
- Founded
- CLNN 2012
- ALLK 2012
- Country
- CLNN United States
- ALLK United States
- Employees
- CLNN N/A
- ALLK N/A
- Industry
- CLNN Biotechnology: Pharmaceutical Preparations
- ALLK Biotechnology: Pharmaceutical Preparations
- Sector
- CLNN Health Care
- ALLK Health Care
- Exchange
- CLNN Nasdaq
- ALLK Nasdaq
- Market Cap
- CLNN 26.1M
- ALLK 23.0M
- IPO Year
- CLNN N/A
- ALLK 2018
- Fundamental
- Price
- CLNN $2.83
- ALLK $0.33
- Analyst Decision
- CLNN Strong Buy
- ALLK Hold
- Analyst Count
- CLNN 5
- ALLK 3
- Target Price
- CLNN $50.20
- ALLK $2.00
- AVG Volume (30 Days)
- CLNN 51.0K
- ALLK 2.2M
- Earning Date
- CLNN 05-07-2025
- ALLK 05-08-2025
- Dividend Yield
- CLNN N/A
- ALLK N/A
- EPS Growth
- CLNN N/A
- ALLK N/A
- EPS
- CLNN N/A
- ALLK N/A
- Revenue
- CLNN $342,000.00
- ALLK N/A
- Revenue This Year
- CLNN N/A
- ALLK N/A
- Revenue Next Year
- CLNN $2,066.67
- ALLK N/A
- P/E Ratio
- CLNN N/A
- ALLK N/A
- Revenue Growth
- CLNN N/A
- ALLK N/A
- 52 Week Low
- CLNN $2.57
- ALLK $0.22
- 52 Week High
- CLNN $9.20
- ALLK $1.56
- Technical
- Relative Strength Index (RSI)
- CLNN 34.63
- ALLK 60.40
- Support Level
- CLNN $2.76
- ALLK $0.31
- Resistance Level
- CLNN $3.18
- ALLK $0.33
- Average True Range (ATR)
- CLNN 0.25
- ALLK 0.00
- MACD
- CLNN 0.05
- ALLK 0.00
- Stochastic Oscillator
- CLNN 38.33
- ALLK 78.50
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
About ALLK Allakos Inc.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation. Its portfolio consists of antibodies that target receptors, particularly Siglec-6, Siglec-8 and other anti-Siglec antibodies, including some antibodies in preclinical development.